DMK Pharmaceuticals Corp
DMKDelisted Mar 21, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000887247
DMK Pharmaceuticals Corp was delisted on Mar 21, 2024; its insiders filed their last Form 4 on Nov 2, 2023; 29 institutions reported holding it in 13F filings for Q4 2023, worth $350.4K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 29
- Q4 2023, +4 vs. previous quarter
- 13F value
- $350.4K
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Superinvestors holding DMK, Q4 2023
No superinvestor reported holding DMK at the end of Q4 2023.
Latest insider trades
Open-market purchases and sales by DMK Pharmaceuticals Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 22, 2022 (view filing) | Mar 18 | 4 days | Moss Ronald B.Chief Medical Officer | SSale | −8.20K | $0.60 | −$4.92K | −3.9%201.9K after | |
| Mar 22, 2022 (view filing) | Mar 18 | 4 days | Marguglio David J.SVP and Chief Business Officer | SSale | −11.9K | $0.60 | −$7.12K | −4.8%233.9K after | |
| Mar 22, 2022 (view filing) | Mar 18 | 4 days | Carlo Dennis J PhDPresident & CEO | SSale | −10.5K | $0.60 | −$6.29K | −3.5%285.9K after | |
| Mar 22, 2022 (view filing) | Mar 18 | 4 days | Benedicto David C.Chief Financial Officer | SSale | −3.60K | $0.61 | −$2.20K | −8.3%39.9K after | |
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | Benedicto David C.Chief Financial Officer | SSale | −13.6K | $0.79 | −$10.7K | −23.8%43.5K after | |
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | Moss Ronald B.Chief Medical Officer | SSale | −35.6K | $0.79 | −$28.1K | −14.5%210.1K after | |
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | Marguglio David J.SVP and Chief Business Officer | SSale | −50.8K | $0.79 | −$40.1K | −16.4%258.8K after | |
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | Carlo Dennis J PhDPresident & CEO | SSale | −47.9K | $0.79 | −$37.8K | −13.9%296.4K after |
Top 10 13F holders, Q4 2023
The largest institutional positions in DMK Pharmaceuticals Corp at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 106,209 | $74.4K | 0.00% | +71,503+206.0% | Added |
| Northern Trust Corp | 103,493 | $72.5K | 0.00% | +103,493 | New |
| Geode Capital Management, LLC | 71,098 | $49.8K | 0.00% | +17,056+31.6% | Added |
| Tower Research Capital LLC (TRC) | 65,203 | $45.6K | 0.00% | +41,160+171.2% | Added |
| BlackRock Inc. | 38,735 | $27.1K | 0.00% | −795−2.0% | Reduced |
| Vanguard Group Inc | 33,990 | $23.8K | 0.00% | +3,900+13.0% | Added |
| Virtu Financial LLC | 22,185 | $16.0K | 0.00% | +3,466+18.5% | Added |
| Susquehanna International Group, LLP | 20,237 | $14.2K | 0.00% | +20,237 | New |
| Two Sigma Securities, LLC | 18,059 | $12.6K | 0.00% | −11,649−39.2% | Reduced |
| HRT Financial LP | 16,558 | $11.0K | 0.00% | +16,558 | New |